Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032

This ‘Chronic Spontaneous Urticaria- Epidemiology Forecast to 2032' report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Spontaneous Urticaria Understanding

Chronic urticaria is a debilitating disease characterized by itching and hives with or without angioedema, lasting for more than 6 weeks. Chronic urticaria might be triggered due to stimuli such as stroking or scratching the skin, exercise, emotional upset (cholinergic urticaria), cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Urticaria induced, thus, is known as chronic induced urticaria (CIndU). However, more commonly chronic urticaria is endogenous and independent of any external causes. This urticaria is known as chronic spontaneous urticaria (CSU).

Historically, the term chronic “idiopathic” urticaria was used for years as CSU's underlying cause remained unknown. This remains true for a major subpopulation of patients. However, it is now understood that in about 40-45% of Chronic Spontaneous Urticaria patients, autoimmunity is the cause. Urticaria is common; it is estimated that 25% of the population suffers from it at one point in their life. At any single time, 0.5-1% of the population suffer from chronic urticaria. Two-thirds of chronic urticaria cases are spontaneous, with females twice as likely to be affected as males.

Diagnosis rates in these patients are lower as patients are likely to use anti-inflammatory OTC products for self-treatment. Various guidelines for treatment such as EAACI/Ga2LEN/EDF/WAO and AAAAI/ACAAI are available for the treatment of Chronic Spontaneous Urticaria. The mainstay of initial treatment remains modern second-generation antihistamines. The frontline antihistamine treatment is effective in ~50% of Chronic Spontaneous Urticaria patients. Currently used treatments are Xolair Prescription, antihistamine, oral corticosteroids, leukotriene receptor antagonists, immunosuppressive agents.

There are a large number of alternative treatments for antihistamines refractory patients, such as corticosteroids, leukotriene antagonists, antidepressants, etc. but the evidence of efficacy for most is weak. In 2014, Roche and Novartis' Xolair (Omalizumab) an anti-IgE monoclonal antibody, became only other therapy, apart from antihistamines to have FDA approval in the treatment of Chronic Spontaneous Urticaria refractory to H1 antihistamine treatment.

Currently, there are a lot of clinical trials ongoing in Chronic Spontaneous Urticaria. Novartis' Ligelizumab, a monoclonal anti-IgE antibody has shown superior efficacy over Omalizumab in phase2b and is currently being evaluated in phase 3 trial. Sanofi and Regeneron's Dupixent (dupilumab), already approved in atopic dermatitis is being evaluated in phase III for Chronic Spontaneous Urticaria. Various other emerging drugs in various phases of trials are Rilzabrutinib (Sanofi/Regeneron), Remibrutinib (Novartis), Benralizumab (AstraZeneca), Fenebrutinib (Genentech), KPL-716 (Kiniksa Pharma), UB-221 (United BioPharma), Mepolizumab (GlaxoSmithKline), AK002 (Allakos).

However, there are still few unmet needs in the understanding of disease etiology in cases where autoimmunity is ruled out. Quality of life is severely impacted in Chronic Spontaneous Urticaria patients due to unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement. Patients with Chronic Spontaneous Urticaria often exhibit psychiatric comorbidities. Chronic Spontaneous Urticaria also has a large direct and indirect economic impact due to increased healthcare cost because of continued medication to control symptoms, and frequent, often unanticipated healthcare visits.

Chronic Spontaneous Urticaria Epidemiology

The Chronic Spontaneous Urticaria epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Spontaneous Urticaria epidemiology segmented as Total Prevalent cases of Chronic Spontaneous Urticaria, Gender-specific Cases of Chronic Spontaneous Urticaria, and Age-specific cases of Chronic Spontaneous Urticaria. The report includes the prevalent scenario of Chronic Spontaneous Urticaria in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise-Chronic Spontaneous Urticaria Epidemiology

The epidemiology segment also provides the Chronic Spontaneous Urticaria epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Chronic Spontaneous Urticaria associated in 7MM countries was estimated to be 1,848,622 cases in 2021 and expected to increase at a CAGR of 0.33% for the study period, i.e., 2019-2032.

• As per the estimates, United States has the highest prevalence population of Chronic Spontaneous Urticaria in the 7MM.

Among the EU5 countries, Germany had the highest prevalent population of Chronic Spontaneous Urticaria. On the other hand Spain had the lowest prevalent population. In 7MM, Spain had the lowest number of cases i.e. 178,389 cases in 2021.

Scope of the Report

• Chronic Spontaneous Urticaria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Chronic Spontaneous Urticaria Epidemiology Report and Model provides an overview of the risk factors and global trends of Chronic Spontaneous Urticaria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Chronic Spontaneous Urticaria in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Spontaneous Urticaria
• The report provides the segmentation of the Chronic Spontaneous Urticaria epidemiology by prevalent cases of Chronic Spontaneous Urticaria in 7MM
• The report provides the segmentation of the Total Prevalent cases of Chronic Spontaneous Urticaria, Gender-specific Cases of Chronic Spontaneous Urticaria, and Age-specific cases of Chronic Spontaneous Urticaria in the 7MM

Report Highlights

• 11-year Forecast of Chronic Spontaneous Urticaria epidemiology
• 7MM Coverage
• Total Prevalent cases of Chronic Spontaneous Urticaria
• Gender-specific Cases of Chronic Spontaneous Urticaria
• Age-specific cases of Chronic Spontaneous Urticaria

KOL Views

The publisher interviews KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Chronic Spontaneous Urticaria?
• What are the Key Findings of Chronic Spontaneous Urticaria epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2022-2032)?
• What would be the total number of patients with Chronic Spontaneous Urticaria across the 7MM during the forecast period (2022-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2022-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2022-2032)?
• What are the disease risk, burden, and unmet needs of Chronic Spontaneous Urticaria?
• What are the currently available treatments for Chronic Spontaneous Urticaria?

Reasons to Buy

The Chronic Spontaneous Urticaria Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Chronic Spontaneous Urticaria market
• Quantify patient populations in the global Chronic Spontaneous Urticaria market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Spontaneous Urticaria therapeutics in each of the markets covered
• Understand the magnitude of Chronic Spontaneous Urticaria population by its prevalent cases
• Understand the magnitude of Chronic Spontaneous Urticaria population by its clinical manifestation specific cases
• The Chronic Spontaneous Urticaria epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Chronic Spontaneous Urticaria Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032